RetiSpec and Gentex are partnering to develop a technology to detect Alzheimer's disease — potentially years before symptom onset — using a non-invasive and cost-effective eye scan technique. The partnership between the two companies will expedite the development of the technology, with the goal of bringing it to market to advance patient care. "The Gentex-RetiSpec partnership reinforces our commitment to bring to market RetiSpec's novel retinal imaging technology, a widely scalable and affordable way to accurately detect Alzheimer's disease at both the symptomatic and pre-symptomatic stages," Eliav Shaked, CEO of RetiSpec, said in a press release. Currently there is no single test that can confirm the diagnosis of Alzheimer's. Clinicians must rely on patients' medical history and the specific symptoms they are experiencing to diagnose the condition. Laboratory tests and brain imaging techniques also may be used to confirm the diagnosis of Alzheimer's and to rule out any other possible conditions. The partnership will leverage RetiSpec's proprietary imaging technology, which was conceived by researchers at the University of Minnesota Center for Drug Design, to create a new tool that will be able to detect Alzheimer's in its earlier stages.